HomeNewsBusinessMarketsShort Call | Bears aim for Glenmark, bulls ignore Info Edge bleak news, Voltas on block deal, and tale of two streets

Short Call | Bears aim for Glenmark, bulls ignore Info Edge bleak news, Voltas on block deal, and tale of two streets

Yesterday’s profit-booking notwithstanding, Dalal Street is awash with the famed ‘animal spirits’ right now, with participants expecting the benchmarks to gallop to record highs almost every alternate session

June 23, 2023 / 08:41 IST
Story continues below Advertisement
markets
High interest rate is bad for market and corporate earnings but Dalal Street seems to be least bothered.

I think economists as rule... take for granted they know a lot of things. If they really knew so much, they would have all the money and we would have none. - Bernard Baruch

The commentary around interest rates is slowly turning hawkish. Bank of England has raised rates by 50 basis points, a few days back the US Fed warned of more hikes, and back home, the RBI does not seem to cut rates any time soon. In theory, high interest rate is bad for consumer sentiment and corporate earnings. But for now, that seems to be the least of the concerns of investors on Dalal Street.

Story continues below Advertisement

Glenmark Pharma

The stock was among the prominent losers on Thursday after a US FDA warning for the company's manufacturing facility in Monroe, United States. The stock has been a star performer in the pharma pack, up 50 percent in 2023 so far, despite most analysts suggesting caution on the stock. The company is in the midst of resolving issues at its Baddi, Goa and Monroe facilities. But the bigger problem, according to some analysts, is the huge gross debt north of Rs 4,500 crore, and the management has not yet been able to give a clear plan of how it intends to reduce it. Derivatives data indicates short positions are being built in the July futures series.